Navigation Links
Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company
Date:12/16/2009

7';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.silence-therapeutics.com/">www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading European RNAi-focused biotechnology company.

RNA interference (RNAi) is a Nobel Prize winning technology and one of the most exciting areas of drug discovery today. It represents a completely new approach to selectively 'silence' or inactivate disease relevant genes and as such it has the potential to create a new class of therapeutic products. RNAi could therefore offer a therapeutic approach to a broad range of diseases (cancer, infectious diseases, inherited diseases), many of which have been regarded as incurable and are not addressed by current therapeutics, therefore providing a large market opportunity.

Silence Therapeutics has developed a platform of novel short interfering RNA (siRNA) molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including increased stability against nuclease degradation. In addition, the Company has developed a proprietary systemic delivery system, AtuPLEX. This system enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake.

Following the granting of its patents in Europe, the USA and Australia, Silence Therapeutics is one of only two companies worldwide with a proprietary position on composition of matter for siRNA therapeutics.

Silence's lead internal product, Atu027, is a proprietary AtuRNAi molecule in clinical development for systemic cancer indications. Atu027 has successfully completed single and repeat dose toxicology and geno-toxicology studies, as well as a 28-day toxicology study using multiple dosing regimens. In June 2009, the Company started an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid (m
'/>"/>

SOURCE Intradigm Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
2. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
3. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
4. Silence Therapeutics Announces Board Changes
5. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... -- Migranade, Inc. announced today the new migraine medication, ... million U.S. migraine sufferers November, 2014. The medicine is ... cause of migraines and not just the symptoms. While ... Migranade is assured to be a game changer in ... at http://www.migranade.com and will soon hit the ...
(Date:10/31/2014)... , Oct. 31, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ...  What: , Isis Pharmaceuticals, Third Quarter 2014 ... November 7 at 11:30 a.m. ET / 8:30 a.m. ... on the Internet. Simply log onto our website listed ... live event, a replay of the webcast will be ...
(Date:10/30/2014)... CHARLOTTETOWN , Oct. 30, 2014 /CNW/ - Atlantic ... three-year agreement reached between Canada,s ... Jim Keon , President of the Canadian Generic Pharmaceutical ... made the comments while speaking at the Atlantic Summit ... Charlottetown , which is being hosted by the ...
Breaking Medicine Technology:Game Changing Migraine Medication To Be Available November 2014 2Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 2Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 3Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines 2Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines 3
... Texas, Sept. 29 Luminex Corporation (Nasdaq: ... 2010 Prix Galien USA Award for its innovative xTAG® ... named Best Medical Technology at the Prix Galien USA ... 2010, at the American Museum of Natural History in ...
... asked today to make protecting the eyes from ... by increasing the prevalence of UV and eye-health ... as the Surgeon General, and in upcoming healthcare ... the Congressional Vision Caucus, provided the opening remarks ...
Cached Medicine Technology:Luminex Corporation Wins Prestigious 2010 Prix Galien USA Award 2Prevent Blindness America Issues Call-to-Action to Make UV Eye Protection a National Health Priority 2Prevent Blindness America Issues Call-to-Action to Make UV Eye Protection a National Health Priority 3
(Date:10/30/2014)... , A mathematical model developed by NIH grantees predicts ... to prevent HIV infection via vaginal sex, whereas just ... infection via anal sex. This finding helps explain why ... PrEP, in women failed to show efficacy. Participants in ... of Truvada and tenofovir (another antiretroviral) for HIV prevention ...
(Date:10/30/2014)... 30, 2014 Graphics, coding, typography and ... with the craft of web design and require thorough ... a simpler solution to create a website can be ... contact information, customer reviews and Facebook posts all accumulate ... is the next evolution of how a business can ...
(Date:10/30/2014)... Portland, OR (PRWEB) October 30, 2014 ... law firm Hodgkinson Street LLC announces new branding ... Hodgkinson Street Mepham . After David Mepham’s promotion ... revitalizes their brand and website to include Mepham’s name ... leading medical malpractice and mediation firm, the decision to ...
(Date:10/30/2014)... Radio listeners who indicate use of four ... of traditional radio commercials and have overwhelmingly endorsed custom ... a purchasing decision. , Those are some highlights from ... radio marketing company CRN International. The research is now ... respondents who indicated they have purchased or considered purchase ...
(Date:10/30/2014)... Dennis Thompson HealthDay Reporter ... Ebola outbreak in Liberia -- one of three West African ... Health Organization officials said Wednesday. Dr. Bruce Aylward, WHO,s ... number of burials in Liberia and no increase in laboratory-confirmed ... push to tame the epidemic may be making some progress, ...
Breaking Medicine News(10 mins):Health News:Model by NIH grantees explains why HIV prevention dosing differs by sex 2Health News:Facebook Websites In Thirty-Seconds 2Health News:Hodgkinson Street Mepham Rebrands 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3
... Tripura Medical College Sunday here to become the ... region. ,"Tripura Medical College, promoted by ... state government, is the first public private partnership ... said K. Balachandran Nair, chairman-cum-managing director, Universal Empire ...
... Quebec coroner Jacques Ramsay has recommended that Canadians suffering ... (epinephrine) or the Twinject, which// provides a double dose ... deadly situations. He has also called for ... to the patients. ,The recommendations follow the ...
... H5N1 virus in a small duck farm in the southern ... ,An animal health official from Thach Phu district, Ben Tre ... had the H5N1 virus." All 84 ducks on the ... 14 nearby farms tested negative for the virus. ...
... 22 organizations have joined hands, formalizing their consent to ... in the working environment. ,Teaming up ... has been conducting workshops for the companies that believe ... of the national business council is also on the ...
... British Heart Foundation (BHF) suggested that people with advanced heart ... their real age.// ,In ... tissues from heart bypass and transplant patients to study how ... the artery cells divide seven to 13 times more rapidly ...
... University, English cider apples have high levels of phenolics – ... ,Thus, a pint of cider is as effective ... to test cider’s effects by getting 12 volunteers to drink ... of cider in a controlled environment and avoid antioxidants in ...
Cached Medicine News:
... excellent illumination (150'000 to approx. 600'000 ... length of the slit image either ... to 8 mm respectively 1 to ... allowing hairline settings providing unique depth ...
... The AQT-10 is the ultimate in clinical ... to detect the subtle red/green or blue/yellow ... as retinal toxicity (that from Plaquenil, for ... and macular degeneration. Additionally it is fast ...
... The UTAS-E 3000 is the most ... rapid and accurate measurements of retinal ... comprehensive, easy-to-use software available drives this ... such as adjustable contrast pattern stimulation, ...
... VEP technology is designed for productivity and ease ... with doctors from the University of Wisconsin who ... decade on over 5,000 subjects. All of the ... and stored, or can be preset and loaded ...
Medicine Products: